HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 30.49
-0.78 (-2.49%)
At close: Sep 11, 2026
HitGen Market Cap
HitGen has a market cap or net worth of 12.21 billion as of September 11, 2026. Its market cap has increased by 19.57% in one year.
Market Cap
12.21B
Enterprise Value
11.50B
Revenue
644.54M
Ranking
n/a
PE Ratio
86.73
Stock Price
30.49
ChartMarket Cap Chart
Since April 16, 2020, HitGen's market cap has decreased from 18.86B to 12.21B, a decrease of -35.26%. That is a compound annual growth rate of -6.56%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 12.21B | 30.38% |
| Dec 31, 2025 | 9.37B | 90.34% |
| Dec 31, 2024 | 4.92B | -17.81% |
| Dec 29, 2023 | 5.99B | 10.86% |
| Dec 30, 2022 | 5.40B | -42.61% |
| Dec 31, 2021 | 9.41B | -22.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Apr 16, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Anhui Anke Biotechnology (Group) | 13.57B |
| Jinyu Bio-technology | 13.12B |
| GemPharmatech | 12.51B |
| Shanghai Medicilon | 12.43B |
| Inner Mongolia Furui Medical Science | 11.96B |
| Sino Biological,Inc. | 11.68B |
| Chengzhi | 11.38B |
| Chengdu Olymvax Biopharmaceuticals | 11.34B |